A Comparison of the dermaPACE® (Pulsed Acoustic Cellular Expression) Device in Conjunction With Standard of Care Versus Standard of Care Alone in the Treatment of Diabetic Foot Ulcers
NCT ID: NCT01824407
Last Updated: 2014-03-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
90 participants
INTERVENTIONAL
2013-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of the study is to evaluate the ability of the dermaPACE® device to help diabetic foot ulcers heal more quickly. The active study device, the dermaPACE®, will be compared to an inactive look-alike device (called a "Sham") in this study. The sham device will not provide any treatment to your diabetic foot ulcer.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effectiveness of dermaPACE™ Device and Standard Treatment Compared to Standard Treatment Alone for Diabetic Foot Ulcers
NCT00536744
The Effects of High Energy Acoustic Shock Wave Therapy on Local Skin Perfusion and DFUs
NCT03640988
Safety & Efficacy Study for the Use of Extracorporeal Shockwaves in the Treatment of Diabetic Foot Ulcers
NCT00366132
Comparing the Expected Benefit of Extra-corporeal-shockwave Therapy (ESWT) Treatment to Standard Care in Treating Diabetic Foot Ulcers
NCT01499472
The Regeneration Effects of Derma-PACE Shockwave in Chronic Diabetic Ulcers
NCT01219127
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Active device plus standard of care
Active device plus standard of care
Electrohydraulic-generated shock wave
Sham device plus standard of care
dermaPACE device that uses a dummy applicator that does not emit shock waves
Sham device plus standard of care
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Electrohydraulic-generated shock wave
Sham device plus standard of care
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. If female of child-bearing potential, both of the following must be met at Visit 1:
* Practices one of the following methods of contraception and continues through the duration of the study: hormonal contraceptives, IUD, spermicide and barrier or implantable device, and
* Has a negative urine qualitative beta-HCG pregnancy test;
3. If female and post-menopausal one of the following must be met at Visit 1:
* Has had a complete hysterectomy, bilateral salpingo-oophorectomy or tubal ligation or otherwise be incapable of pregnancy, or
* Is postmenopausal for at least one year;
4. Has at least one DFU that is located in the ankle area or below that has persisted a minimum of 30 days prior to Visit 1.
5. Has Type I or Type II Diabetes Mellitus with a HbA1c \<= 11% at Visit 1;
6. Is capable of wound care at home;
7. Has a target ulcer \>= 1.0 cm2 and \<= 16 cm2 at Visits 1 and 2;
8. Has a target ulcer that is Grade 1 or 2, Stage A according to the University of Texas Diabetic Wound Classification system, at Visits 1 and 2
9. In the leg with the target ulcer has an ABI \>= 0.70 and \<= 1.20 OR if the ABI is \>1.20 has a toe pressure \>50 mmHg OR tcpO2 \> 40 mmHg at Visit 1;
10. Subject agrees, or if applicable, the subject's legal representative agrees that the subject can participate in the study
Exclusion Criteria
2. Is nursing or actively lactating;
3. Is morbidly obese (Body Mass Index \>= 40) at Visit 1;
4. Has clinically significant renal disease defined as having an estimated creatinine clearance of \<=40mL/min at Visit 1;
5. Has osteomyelitis in the foot or ankle on which the target ulcer is located at Visit 1 or 2;
6. Has evidence of a prior ulcer in the same area as the target ulcer;
7. Has a target ulcer that has decreased in volume by 50% or more at Visit 2 as compared to the volume at Visit 1;
8. Has multiple foot ulcers that are connected by fistulas or has an ulcer(s) that are within 5 cm of the target ulcer at Visit 1 or 2;
9. Has a target ulcer that tunnels into wound tracks which cannot be fully visualized from the wound surface at Visit 1 or 2;
10. Has active cellulitis either at the site of, or in the surrounding area of, the target ulcer at Visit 1 or 2;
11. Has a target ulcer that has visually purulent exudates or that has malodorous exudates on examination at Visit 1 or 2;
12. Has PVD, per Doppler Ultrasound, requiring vascular surgery intervention at Visit 1 or 2;
13. Requires use of off-loading Diabetic Walker device for the foot intended for study application for a reason other than for a target ulcer on the plantar surface of the foot at Visit 1 or 2;
14. Has had a lower extremity revascularization procedure within eight weeks of Visit 1;
15. Has active Charcot foot at Visit 1 or 2;
16. Has had a surgical procedure to correct biomechanical abnormities within eight weeks of Visit 1;
17. Has had a deep vein thrombosis within six months of Visit 1;
18. Has clinical evidence of lymphedema at Visit 1;
19. Has had chemotherapy within 60 days of Visit 1;
20. Has a life expectancy \<=2 years;
21. Has previously participated in a dermaPACE diabetic foot ulcer study;
22. Has had treatment of the target ulcer with growth factors, prostaglandin therapy, negative pressure or vasodilator therapy within two weeks of Visit 1;
23. Is receiving \>=10 mg/day of steroid therapy;
24. Has sickle cell anemia;
25. Has a known immunodeficiency disorder to include, but not be limited to: AIDS, HIV, etc.
26. Has received radiation treatment within 120 days of Visit 1;
27. Has received treatment with immunosuppressants within sixty days of Visit 1;
28. Has received treatment with biologically active cellular products on the target ulcer, e.g. Apligraf®, Dermagraft®, etc. within sixty days of Visit 1;
29. Has received treatment with acellular (collagen-based) products on the target ulcer, e.g. Alloderm®, Integra®, etc. within 30 days of Visit 1;
30. Has a current history of substance abuse (current is defined as within 120 days of Visit 1);
31. Has a history of major systemic infections requiring hospitalization within three months of Visit 1 ;
32. Has a current malignancy or a history of malignancy within five years, of Visit 1 except for basal cell carcinoma that has been treated with local excision and is no longer present;
33. Has a physical or mental disability or geographical concerns that would inhibit compliance with required study visits;
34. Is planning to undergo an exclusionary treatment or procedure during the study; or
35. Has participated in another investigation within 30 days of Visit 1
22 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
SANUWAVE, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Associated Foot and Ankle Specialists
Phoenix, Arizona, United States
Southern Arizona VA Healthcare System
Tucson, Arizona, United States
Long Beach VA Healthcare System
Long Beach, California, United States
Foot and Ankle Clinic
Los Angeles, California, United States
Alameda County Medical Center - Highlands Campus
Oakland, California, United States
Lucius J. Hill DPM
San Bernardino, California, United States
Paul and Margaret Brand Research Center at Barry University
Hialeah, Florida, United States
The Research Center
Hialeah, Florida, United States
River City Clinical Research
Jacksonville, Florida, United States
St. Paul Medical Research
Miami, Florida, United States
Advanced Pharma CR
Miami, Florida, United States
Northwestern University, Div of Plastic and Reconstructive Surgery
Chicago, Illinois, United States
Foot Healthcare Associates
Southfield, Michigan, United States
Moore Foot and Ankle Specialists
Asheville, North Carolina, United States
Wound Center - ACMH
Kittaning, Pennsylvania, United States
Podiatric Medical Partners of Texas
Dallas, Texas, United States
UT Southwestern Medical Center
Dallas, Texas, United States
Foot and Ankle Associates of SW Virginia
Roanoke, Virginia, United States
The Mayer Institute
Hamilton, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SAN12-DERM02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.